ISSN 1674-3865  CN 21-1569/R
主管:国家卫生和计划生育委员会
主办:中国医师协会
   辽宁省基础医学研究所
   辽宁中医药大学附属医院

Chinese Pediatrics of Integrated Traditional and Western Medicine ›› 2023, Vol. 15 ›› Issue (2): 129-132.doi: 10.3969/j.issn.1674-3865.2023.02.008

Previous Articles     Next Articles

Research progress of Perampanel monotherapy in the treatment of epilepsy in children

WU Mei, TANG Yongzai, QIAO Pei, DONG Yan   

  1. Department of Neurology, Tangshan Maternal and Child Health Hospital Affiliated to North China University of Science and Technology, Tangshan 063000, China

  • Received:2022-12-03 Published:2023-04-25 Online:2023-04-25
  • Contact: DONG Yan,E-mail:dongyan012000@126.com

Abstract: Perampanel(PER), as the first highly selective non-competitive α-amino-3-hydroxy-5-methyl-4-isoxy-5-methyl -4-isooxazolpropionic acid (AMPA) receptor antagonist approved for use, is currently approved in China for the treatment of focal epilepsy (with or without progression to bilateral tonic-clonic seizures) in adults and children aged 4 years and older. This drug was marketed late in China, and was mostly used for additive therapy in adults and children. There is little experience in the application of monotherapy for children's epilepsy. This article reviewed the mechanism of action, pharmacokinetics, efficacy and safety of PER in the treatment of childhood epilepsy at home and abroad, in order to provide reference for clinicians. 

Key words:

Epilepsy, Perampanel, Monotherapy, Efficacy, Safety